Against the backdrop of recent clinical research to further develop therapeutic options for patients with EGFR exon 20 insertions, QuIP is now offering a proficiency test on this topic. Various clinical studies have also been conducted, where patients with insertions in exon 20 of the EGFR gene were targeted (insertions of known significance in the region between amino acids D761 to C775; Vyse & Huang, Signal Transduction and Targeted Therapy, 2019). The testing for EGFR mutation insertions is therefore the goal of the QuIP proficiency test.
Registration for this EGFR Exon 20 Ins. proficiency test is possible starting immediately until September 6th 2021 via www.qualityinpatholgy.com. The proficiency test will have 2 runs (splits 1 & 2). Please note that participants from Russia, Kuwait, Saudi Arabia and UAE can only register for split 2. The trial period for split 1 is 27.09.-22.10.2021 and for split 2 04.-29.10.2021. Participation is free of charge. It is advisable to read the instructions for the proficiency test before registering.